Treatment with pegylated interferon alfa-2a in chronic hepatitis B infection in a regional hospital

被引：0
|
作者：
Kei, P. [1 ]
Yuen, I. [1 ]
Lam, J. T. W. [1 ]
Hui, Y. T. [1 ]
机构：
[1] Queen Elizabeth Hosp, Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2011年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
下载
收藏
页码：144 / 144
页数：1
相关论文
共 50 条
  • [31] Acute inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alfa-2a in a patient with chronic hepatitis C virus infection: A case report
    Lahbabi M.
    Ghissassi M.
    Belahcen F.
    Ibrahimi S.A.
    Aqodad N.
    Journal of Medical Case Reports, 6 (1)
  • [32] Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: a randomized trial
    Zaigham Abbas
    Mohammad Sadik Memon
    Muhammad Amir Umer
    Minaam Abbas
    Lubna Shazi
    World Journal of Hepatology, 2016, (14) : 625 - 631
  • [33] Secondary bronchiolitis obliterans organizing pneumonia during treatment of chronic hepatitis C: role of pegylated interferon alfa-2a
    Martins, Ronaldo Soares
    Machado, Juliano Antunes
    Teixeira, Rosangela
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2012, 45 (05) : 655 - 656
  • [34] Preliminary on-treatment data from a phase 2 study evaluating VIR-2218 in combination with pegylated interferon alfa-2a in participants with chronic hepatitis B infection
    Yuen, Man-Fung
    Lim, Young-Suk
    Cloutier, Daniel
    Shen, Ling
    Arizpe, Andre
    Pang, Phil
    Tay, Chin
    Thanawala, Vaidehi
    Gupta, Sneha V.
    Cathcart, Andrea
    Gane, Edward
    JOURNAL OF HEPATOLOGY, 2021, 75 : S738 - S739
  • [35] Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial
    Abbas, Zaigham
    Memon, Mohammad Sadik
    Umer, Muhammad Amir
    Abbas, Minaam
    Shazi, Lubna
    WORLD JOURNAL OF HEPATOLOGY, 2016, 8 (14) : 625 - 631
  • [36] Pericarditis and chronic inflammatory demyelinating polyneuropathy during therapy with pegylated interferon alfa-2a for chronic hepatitis C
    Kazuaki Nishio
    Takeshi Konndo
    Shunichi Okada
    Machiko Enchi
    World Journal of Hepatology, 2010, 2 (09) : 358 - 361
  • [37] Pericarditis and chronic inflammatory demyelinating polyneuropathy during therapy with pegylated interferon alfa-2a for chronic hepatitis C
    Nishio, Kazuaki
    Konndo, Takeshi
    Okada, Shunichi
    Enchi, Machiko
    WORLD JOURNAL OF HEPATOLOGY, 2010, 2 (09) : 358 - 361
  • [38] HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study
    Al Ashgar, Hamad
    Peedikayil, Musthafa C.
    Al Quaiz, Mohammed
    Al Sohaibani, Fahad
    Al Fadda, Abdulrahman
    Khan, Mohammed Q.
    Thoralsson, Einar
    Al Thawadi, Sahar
    Al Jedai, Ahmed
    Al Kahtani, Khalid
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2017, 23 (03): : 190 - 198
  • [39] Histologic improvement following treatment with once weekly pegylated interferon alfa-2a (Pegasys™) and thrice weekly interferon alfa-2a (Roferon™)in patients with chronic hepatitis C and compensated cirrhosis.
    Balart, LA
    Lee, SS
    Schiffman, M
    Reindollar, R
    Minuk, G
    Pockros, P
    Hoffman, J
    Depamphilis, J
    GASTROENTEROLOGY, 2000, 118 (04) : A961 - A961
  • [40] Enhanced efficacy of pegylated (40kDa) interferon alfa-2A (Pegasys™) compared with interferon alfa-2A (Roferon-A™) for chronic hepatitis C in Blacks.
    Shiffman, ML
    Fromm, H
    Mills, P
    Moonka, DK
    Fried, MW
    Berg, C
    Sherman, M
    Smith, C
    Marsano, L
    Reddy, KR
    Brunda, MJ
    DePamphilis, J
    HEPATOLOGY, 2000, 32 (04) : 348A - 348A
12345